Postoperative Interferon Alpha Treatment Of Patients With Hepatocellular Carcinoma: Expression Of P48 Using Tissue Microarray

Hui-Chuan Sun

DOI: https://doi.org/10.1007/978-1-4020-9804-8_23

2009-01-01

Abstract:Hepatocellular carcinoma (HCC) is a major health problem in China and the third most common cause of cancer death in the world (Parkin et al., 2005). Surgical resection can have a curative outcome, but > 50% of patients will have recurrence in the first 5 years after resection (Poon, 2007), and the recurrence usually results in death (Regimbeau et al., 2004). No standard postoperative adjuvant therapy has yet been established (Sun and Tang, 2003). In a previous study, we demonstrated that interferon-α (IFN-α) delays tumor growth and inhibits metastasis in a nude mouse model (Wang et al., 2000). Further studies revealed that both antiangio-genesis and antiproliferative effects are involved in the antitumor effect in the HCC model (Wang et al., 2003; Wu et al., 2004, 2005). In addition to the direct antitumor effect, the antivirus effect may also be involved in the prevention of recurrence of HCC. Some reports have indicated that long-term IFN-α reduces the incidence of HCC in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (Lin et al., 2007; Y u et al., 2006).